vs

Side-by-side financial comparison of Eventbrite, Inc. (EB) and MACROGENICS INC (MGNX). Click either name above to swap in a different company.

Eventbrite, Inc. is the larger business by last-quarter revenue ($73.5M vs $41.2M, roughly 1.8× MACROGENICS INC). On growth, MACROGENICS INC posted the faster year-over-year revenue change (113.0% vs -3.9%). MACROGENICS INC produced more free cash flow last quarter ($42.8M vs $-60.9M). Over the past eight quarters, MACROGENICS INC's revenue compounded faster (112.8% CAGR vs -7.7%).

Eventbrite is an American live events marketplace and website. The service allows users to browse, create, and promote local events. It is free to publish unlimited events of any size on Eventbrite.

MacroGenics Inc is a clinical-stage biopharmaceutical firm specializing in the research and development of novel immunotherapies for cancer and autoimmune disorders. Its core product pipeline centers on monoclonal antibody-based treatments, with key programs targeting solid tumors and hematological malignancies, supported by partnerships with global pharmaceutical partners.

EB vs MGNX — Head-to-Head

Bigger by revenue
EB
EB
1.8× larger
EB
$73.5M
$41.2M
MGNX
Growing faster (revenue YoY)
MGNX
MGNX
+116.9% gap
MGNX
113.0%
-3.9%
EB
More free cash flow
MGNX
MGNX
$103.6M more FCF
MGNX
$42.8M
$-60.9M
EB
Faster 2-yr revenue CAGR
MGNX
MGNX
Annualised
MGNX
112.8%
-7.7%
EB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EB
EB
MGNX
MGNX
Revenue
$73.5M
$41.2M
Net Profit
$-8.2M
Gross Margin
68.1%
Operating Margin
-12.4%
-29.3%
Net Margin
-11.1%
Revenue YoY
-3.9%
113.0%
Net Profit YoY
2.5%
EPS (diluted)
$-0.08
$-0.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EB
EB
MGNX
MGNX
Q4 25
$73.5M
$41.2M
Q3 25
$71.7M
$72.8M
Q2 25
$72.8M
$22.2M
Q1 25
$73.8M
$13.2M
Q4 24
$76.5M
$19.4M
Q3 24
$77.8M
$110.7M
Q2 24
$84.6M
$10.8M
Q1 24
$86.3M
$9.1M
Net Profit
EB
EB
MGNX
MGNX
Q4 25
$-8.2M
Q3 25
$6.4M
$16.8M
Q2 25
$-2.1M
$-36.3M
Q1 25
$-6.6M
$-41.0M
Q4 24
$-8.4M
Q3 24
$-3.8M
$56.3M
Q2 24
$1.1M
$-55.7M
Q1 24
$-4.5M
$-52.2M
Gross Margin
EB
EB
MGNX
MGNX
Q4 25
68.1%
Q3 25
67.9%
Q2 25
67.5%
Q1 25
66.9%
Q4 24
68.2%
98.8%
Q3 24
68.5%
99.8%
Q2 24
70.9%
98.4%
Q1 24
71.0%
97.0%
Operating Margin
EB
EB
MGNX
MGNX
Q4 25
-12.4%
-29.3%
Q3 25
-1.3%
25.6%
Q2 25
-8.7%
-165.3%
Q1 25
-13.2%
-323.1%
Q4 24
-10.2%
-273.0%
Q3 24
-11.5%
48.9%
Q2 24
-7.6%
-538.9%
Q1 24
-8.8%
-590.4%
Net Margin
EB
EB
MGNX
MGNX
Q4 25
-11.1%
Q3 25
8.9%
23.1%
Q2 25
-2.9%
-163.0%
Q1 25
-9.0%
-311.1%
Q4 24
-11.0%
Q3 24
-4.8%
50.9%
Q2 24
1.3%
-515.6%
Q1 24
-5.2%
-573.3%
EPS (diluted)
EB
EB
MGNX
MGNX
Q4 25
$-0.08
$-0.23
Q3 25
$0.06
$0.27
Q2 25
$-0.02
$-0.57
Q1 25
$-0.07
$-0.65
Q4 24
$-0.09
$-0.24
Q3 24
$-0.04
$0.90
Q2 24
$0.01
$-0.89
Q1 24
$-0.05
$-0.84

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EB
EB
MGNX
MGNX
Cash + ST InvestmentsLiquidity on hand
$299.9M
$57.2M
Total DebtLower is stronger
$144.4M
Stockholders' EquityBook value
$179.1M
$55.6M
Total Assets
$647.2M
$256.8M
Debt / EquityLower = less leverage
0.81×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EB
EB
MGNX
MGNX
Q4 25
$299.9M
$57.2M
Q3 25
$80.1M
Q2 25
$130.7M
Q1 25
$145.6M
Q4 24
$441.5M
$182.8M
Q3 24
$24.7M
$179.6M
Q2 24
$56.7M
$83.9M
Q1 24
$113.7M
$80.4M
Total Debt
EB
EB
MGNX
MGNX
Q4 25
$144.4M
Q3 25
$174.9M
Q2 25
$241.3M
Q1 25
$241.0M
Q4 24
$240.7M
Q3 24
$240.4M
Q2 24
$358.7M
Q1 24
$358.2M
Stockholders' Equity
EB
EB
MGNX
MGNX
Q4 25
$179.1M
$55.6M
Q3 25
$189.1M
$67.0M
Q2 25
$177.2M
$46.6M
Q1 25
$173.3M
$79.1M
Q4 24
$170.2M
$116.1M
Q3 24
$179.8M
$120.1M
Q2 24
$176.2M
$57.8M
Q1 24
$184.1M
$106.2M
Total Assets
EB
EB
MGNX
MGNX
Q4 25
$647.2M
$256.8M
Q3 25
$744.6M
$270.8M
Q2 25
$784.1M
$245.4M
Q1 25
$812.3M
$224.6M
Q4 24
$752.3M
$261.7M
Q3 24
$817.4M
$264.5M
Q2 24
$894.5M
$201.1M
Q1 24
$952.2M
$248.3M
Debt / Equity
EB
EB
MGNX
MGNX
Q4 25
0.81×
Q3 25
0.92×
Q2 25
1.36×
Q1 25
1.39×
Q4 24
1.41×
Q3 24
1.34×
Q2 24
2.04×
Q1 24
1.95×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EB
EB
MGNX
MGNX
Operating Cash FlowLast quarter
$-60.8M
$43.0M
Free Cash FlowOCF − Capex
$-60.9M
$42.8M
FCF MarginFCF / Revenue
-82.8%
103.8%
Capex IntensityCapex / Revenue
0.0%
0.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$17.6M
$-83.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EB
EB
MGNX
MGNX
Q4 25
$-60.8M
$43.0M
Q3 25
$36.7M
$-30.2M
Q2 25
$-17.5M
$-47.0M
Q1 25
$59.4M
$-46.9M
Q4 24
$-45.3M
$-38.4M
Q3 24
$44.6M
$60.2M
Q2 24
$-32.3M
$-44.5M
Q1 24
$68.6M
$-45.6M
Free Cash Flow
EB
EB
MGNX
MGNX
Q4 25
$-60.9M
$42.8M
Q3 25
$36.6M
$-30.6M
Q2 25
$-17.5M
$-47.7M
Q1 25
$59.4M
$-47.4M
Q4 24
$-45.3M
$-39.0M
Q3 24
$44.4M
$59.6M
Q2 24
$-32.4M
$-45.5M
Q1 24
$68.2M
$-47.1M
FCF Margin
EB
EB
MGNX
MGNX
Q4 25
-82.8%
103.8%
Q3 25
51.1%
-42.0%
Q2 25
-24.1%
-214.5%
Q1 25
80.4%
-359.5%
Q4 24
-59.2%
-201.7%
Q3 24
57.1%
53.8%
Q2 24
-38.3%
-421.6%
Q1 24
79.1%
-517.4%
Capex Intensity
EB
EB
MGNX
MGNX
Q4 25
0.0%
0.6%
Q3 25
0.0%
0.6%
Q2 25
0.0%
3.2%
Q1 25
0.1%
4.0%
Q4 24
0.0%
3.2%
Q3 24
0.2%
0.5%
Q2 24
0.1%
9.6%
Q1 24
0.4%
16.0%
Cash Conversion
EB
EB
MGNX
MGNX
Q4 25
Q3 25
5.76×
-1.79×
Q2 25
Q1 25
Q4 24
Q3 24
1.07×
Q2 24
-30.37×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EB
EB

US$52.0M71%
Other$21.6M29%

MGNX
MGNX

Revenue From Collaborative Agreements$20.3M49%
Contract Manufacturing$11.3M27%
Other$9.7M23%

Related Comparisons